LIFS Stock Overview
A development stage company, focuses on establishing stem cell therapy based clinics worldwide. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Life Stem Genetics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.01 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | -99.96% |
3 Year Change | 0% |
5 Year Change | -99.00% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
LIFS | US Healthcare | US Market | |
---|---|---|---|
7D | 0% | -2.7% | 1.2% |
1Y | -100.0% | -5.1% | 21.0% |
Return vs Industry: LIFS underperformed the US Healthcare industry which returned -5.1% over the past year.
Return vs Market: LIFS underperformed the US Market which returned 21% over the past year.
Price Volatility
LIFS volatility | |
---|---|
LIFS Average Weekly Movement | n/a |
Healthcare Industry Average Movement | 6.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 18.5% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LIFS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine LIFS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | n/a | Gloria Simov | n/a |
Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. Its products and services include nutraceutical and medical supplements, and IV nutritional cocktails; stem cell banking services; stem cell treatments for degenerative conditions, hyperbaric oxygen therapy, cancer treatments, and weight loss; anti-aging stem cell therapy; anti-viral therapy; and adistem stem cell treatments for orthopedics, neurological, and lung diseases. Life Stem Genetics Inc. has a strategic collaborative agreement with American CryoStem Corporation.
Life Stem Genetics Inc. Fundamentals Summary
LIFS fundamental statistics | |
---|---|
Market cap | US$245.00 |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs LIFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LIFS income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did LIFS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/11 19:47 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | N/A |
Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Life Stem Genetics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.